Position in SCLX
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$19
-$17 QoQ
Shares Held
3
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Parallel Advisors, LLC holds $104,513,791 across 18 Drug Manufacturers - General names. SCLX ranks #18 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
30,405 | $27,965,606 | |
| 2 | ABBV |
AbbVie Inc.
|
103,875 | $22,591,773 | |
| 3 | JNJ |
Johnson & Johnson
|
80,406 | $19,654,442 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
75,984 | $10,589,890 | |
| 5 | MRK |
Merck & Co., Inc.
|
56,169 | $6,756,569 | |
| 6 | PFE |
Pfizer Inc
|
129,199 | $3,627,907 | |
| 7 | AMGN |
Amgen Inc
|
10,183 | $3,582,888 | |
| 8 | NVS |
Novartis AG
|
16,366 | $2,499,906 |
All Filings in SCLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $19 | 3 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $36 | 3 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $255 | 13 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $17 | 3 | Shares | Sole | 2025-07-08 | |
| No filing history on record for this holder in this stock. | ||||||